Completed OBSERVATIONAL NCT00792350

INSIGHT - Post Marketing Surveillance (INSIGHT)

International Study With Nexavar About Safety and Efficacy in Carcinoma Hepatocellular Therapy (HCC)

Sponsor: Bayer

Interventions Sorafenib (Nexavar, BAY43-9006)

Updated 9 times since 2017 Last updated: May 13, 2014 Started: Apr 30, 2008 Primary completion: Oct 31, 2013 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00792350, this observational or N/A phase trial focuses on Carcinoma, Hepatocellular and remains completed. Sponsored by Bayer, it has been updated 9 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Feb 2020 — Jan 2021 [monthly]

Completed
Jun 2018 — Feb 2020 [monthly]

Completed

▶ Show 4 earlier versions

May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Apr 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Many Locations, Austria
• Many Locations, Germany